Goldstein Brahm, Geldziler Brian, Bjerre Jens, Seremetis Stephanie
Novo Nordisk Inc., 100 College Road West, Princeton, NJ, United States.
Transfus Apher Sci. 2008 Feb;38(1):25-32. doi: 10.1016/j.transci.2007.12.002. Epub 2008 Feb 11.
Children and adolescents comprise a significant proportion of the hemophilia population, including those patients who have developed inhibitors to factor VIII or FIX. We examine the use of rFVIIa for the treatment of bleeding episodes and the prevention of bleeding in children and adolescents with hemophilia A and B with inhibitors, focusing on registry data and recent clinical trial results. Based on this review of the literature, we conclude that recombinant FVIIa is safe and effective for use in controlling bleeding in these patient populations.
儿童和青少年在血友病患者群体中占相当大的比例，包括那些已产生针对凝血因子VIII或FIX抑制剂的患者。我们研究了重组活化凝血因子VII（rFVIIa）在治疗血友病A和B且伴有抑制剂的儿童及青少年出血发作和预防出血方面的应用，重点关注注册数据和近期临床试验结果。基于对文献的这一综述，我们得出结论，重组凝血因子VIIa用于控制这些患者群体的出血是安全有效的。
